Efstathiou, Eleni

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 4,407

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 2,796

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine

Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research

Cited by 594

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 428

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 130

Metastatic prostate cancer and the bone: significance and therapeutic options

Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology

Bone health and treatmentsProstate Cancer Treatment and Research

Cited by 101

Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells

Wan, X., Liu, J., Lu, J.-F., Tzelepi, V., Yang, J., Starbuck, M. W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E. S., et al. (2012) · Clinical Cancer Research

Wnt/β-catenin signaling in development and cancerProstate Cancer Treatment and Research

Cited by 79

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Chi, K. N. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J. J., Gomes, A. J. P. D. S., Rathkopf, D., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 12